After service as a bridesmaid 27 times, a young adult female wrestles with the idea of standing by her sister’s side as her sib marries the man she’s on the QT in erotic love with.
Download 27 Dresses: DivX, DVD or iPod/Zune Version
Tuesday, 2 September 2008
Saturday, 23 August 2008
ImmuneRegen(R) BioSciences Confirms Homspera(R) Advances Wound Healing In Topical Application
�ImmuneRegen� BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug prospect, Homspera�, has accelerated the healing process of rich, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology exploitation company that also provides contracted preclinical research services. The study results add to the body of evidence of Homspera's power to get wound healing and farther support the potential application of Homspera in diverse areas such as thermal and chemical burns, field of honor trauma, and wounds such as diabetic and air pressure ulcers, as well as surgical and traumatic wounds.
Bio-Quant performed the 24-day study on Yorkshire pigs, which have similar hide and wound-healing mechanisms as humans and are therefore a favorite model for wound-healing studies. Four sets of four wounds on each of two pigs were treated with dissimilar concentrations of Homspera and compared with a four-wound control lay out. Homspera's healing effect was pronounced on both the size of the injury and its rate of closure. The excisions were made through the full thickness of the dermic layers, and then topically treated with Homspera. Homspera stimulated the deposition of collagen, which is the main protein in the body's connection tissue, by increasing the accumulation of fibroblasts, the cells that produce collagen. Homspera rock-bottom wound size of it an average of 21 percent over the control at Day 10, 27 percent at Day 14, and 36 percent at Day 21. Additional research, studies and testing of Homspera volition be compulsory to gratify FDA and other applicable laws and regulations before any conclusions can be made around the manipulation of Homspera for future product development or for human therapeutical treatment.
"Homspera reduces the wound area of full-thickness excisional wounds, likely by increasing fibroblast proliferation and collagen deductive reasoning and dethronement throughout the proliferative and remodeling stages of lesion repair," explained Hal Siegel, Ph.D., ImmuneRegen VP and chief scientific officer. "In fact, Homspera may accelerate all phases of wound closure, peradventure stimulating the earliest stages via the hematopoietic base cell activeness previously described."
Said Michael K. Wilhelm, ImmuneRegen chairman and CEO, "From the results of our versatile studies, Homspera continues to show noteworthy versatility as a stand-alone therapeutic. We are development a numeral of formulations for unmilitary and military uses, such as the spray-on lotion we ar exploring with BioCure, Inc. and the topical gelatin application we are exploring with DelSite, that we believe will strengthen our position for out-licensing and/or expedited product development for Homspera."
About Bio-Quant, Inc.
Bio-Quant, Inc. is a revenue-generating biotechnology company located in San Diego, Calif., focused on developing proprietorship biopharmaceutical drug candidates in the areas of oncology, and microbial and immunologic diseases, as well as providing contract preclinical development and drug discovery services to other biopharmaceutical companies. Bio-Quant has several compounds in assorted stages of preclinical development, as well as relationships with several major biopharmaceutical companies for its services business. Bio-Quant applies its expertise in immunology and oncology toward developing biopharmaceuticals to fight diseases such as mastermind and colon cancers, lymphoma, leukemia, vitiligo and cirrhosis. For more information, please visit hTTP://www.bio-quant.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a completely owned underling of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera�, an adult prow cell fighting compound that in study results has been shown to rectify and fortify the resistant system and enhance wound healing. To advance its mission, the Scottsdale, Arizona, based company has bad numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, Lovelace Respiratory Research Institute, HemoGenix and Virion Systems, Inc. http://www.immuneregen.com
Statements about ImmuneRegen's future expectations, including statements about the potential role and scientific results for ImmuneRegen's do drugs candidates, science and engineering, and all other statements in this press release other than historical facts, are "modern statements" inside the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such modern statements be subject to the dependable harbors created thereby. These future events may non occur as and when expected, if at all, and, together with ImmuneRegen's business, ar subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a solution of a number of factors, including the fact that results of the studies involved only a small number of Yorkshire pigs, the studies were limited in scope, the uncertainties inbuilt in research and exploitation collaborations, presymptomatic and clinical trials and product development programs (including, but non limited to the fact that future results or research and development efforts may prove less supporting than electric current results or cause side effects non observed in current preclinical trials), the evaluation of potential opportunities, the stratum of bodied expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the threesome months ended March 31, 2008, and on Form 10-KSB for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. There are no guarantees that whatsoever of ImmuneRegen's proposed products will test to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
ImmuneRegen BioSciences, Inc.
More info
Bio-Quant performed the 24-day study on Yorkshire pigs, which have similar hide and wound-healing mechanisms as humans and are therefore a favorite model for wound-healing studies. Four sets of four wounds on each of two pigs were treated with dissimilar concentrations of Homspera and compared with a four-wound control lay out. Homspera's healing effect was pronounced on both the size of the injury and its rate of closure. The excisions were made through the full thickness of the dermic layers, and then topically treated with Homspera. Homspera stimulated the deposition of collagen, which is the main protein in the body's connection tissue, by increasing the accumulation of fibroblasts, the cells that produce collagen. Homspera rock-bottom wound size of it an average of 21 percent over the control at Day 10, 27 percent at Day 14, and 36 percent at Day 21. Additional research, studies and testing of Homspera volition be compulsory to gratify FDA and other applicable laws and regulations before any conclusions can be made around the manipulation of Homspera for future product development or for human therapeutical treatment.
"Homspera reduces the wound area of full-thickness excisional wounds, likely by increasing fibroblast proliferation and collagen deductive reasoning and dethronement throughout the proliferative and remodeling stages of lesion repair," explained Hal Siegel, Ph.D., ImmuneRegen VP and chief scientific officer. "In fact, Homspera may accelerate all phases of wound closure, peradventure stimulating the earliest stages via the hematopoietic base cell activeness previously described."
Said Michael K. Wilhelm, ImmuneRegen chairman and CEO, "From the results of our versatile studies, Homspera continues to show noteworthy versatility as a stand-alone therapeutic. We are development a numeral of formulations for unmilitary and military uses, such as the spray-on lotion we ar exploring with BioCure, Inc. and the topical gelatin application we are exploring with DelSite, that we believe will strengthen our position for out-licensing and/or expedited product development for Homspera."
About Bio-Quant, Inc.
Bio-Quant, Inc. is a revenue-generating biotechnology company located in San Diego, Calif., focused on developing proprietorship biopharmaceutical drug candidates in the areas of oncology, and microbial and immunologic diseases, as well as providing contract preclinical development and drug discovery services to other biopharmaceutical companies. Bio-Quant has several compounds in assorted stages of preclinical development, as well as relationships with several major biopharmaceutical companies for its services business. Bio-Quant applies its expertise in immunology and oncology toward developing biopharmaceuticals to fight diseases such as mastermind and colon cancers, lymphoma, leukemia, vitiligo and cirrhosis. For more information, please visit hTTP://www.bio-quant.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a completely owned underling of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera�, an adult prow cell fighting compound that in study results has been shown to rectify and fortify the resistant system and enhance wound healing. To advance its mission, the Scottsdale, Arizona, based company has bad numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, Lovelace Respiratory Research Institute, HemoGenix and Virion Systems, Inc. http://www.immuneregen.com
Statements about ImmuneRegen's future expectations, including statements about the potential role and scientific results for ImmuneRegen's do drugs candidates, science and engineering, and all other statements in this press release other than historical facts, are "modern statements" inside the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such modern statements be subject to the dependable harbors created thereby. These future events may non occur as and when expected, if at all, and, together with ImmuneRegen's business, ar subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a solution of a number of factors, including the fact that results of the studies involved only a small number of Yorkshire pigs, the studies were limited in scope, the uncertainties inbuilt in research and exploitation collaborations, presymptomatic and clinical trials and product development programs (including, but non limited to the fact that future results or research and development efforts may prove less supporting than electric current results or cause side effects non observed in current preclinical trials), the evaluation of potential opportunities, the stratum of bodied expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the threesome months ended March 31, 2008, and on Form 10-KSB for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. There are no guarantees that whatsoever of ImmuneRegen's proposed products will test to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
ImmuneRegen BioSciences, Inc.
More info
Wednesday, 13 August 2008
Download Xiu Xiu
 Artist: Xiu Xiu: mp3 download Genre(s): Indie Experimental ROck: Alternative Discography:  The Air Force Year: 2006 Tracks: 11  Life and Live Year: 2005 Tracks: 15  La Foret Year: 2005 Tracks: 11  Live At Radio 3 (june 2004) Year: 2004 Tracks: 4  Fabulous Muscles Year: 2004 Tracks: 10  Promise Year: 2003 Tracks: 10  Live @ Emo's, Austin, TX 18 Nov 03 Year: 2003 Tracks: 8  Fag Patrol Year: 2003 Tracks: 9  A Promise Year: 2003 Tracks: 10  Knife Play Year: 2002 Tracks: 11  Chapel Of The Chimes EP Year: 2002 Tracks: 5  Chapel Of The Chimes Year: 2002 Tracks: 5 Taking their identify from the 1998 Chinese picture Xiu Xiu: The Sent Down Girl, post-punk throwbacks Xiu Xiu were formed in San Jose, CA, by Cory McCullough, Yvonne Chen (publisher of the indie zine Zum), Lauren Andrews, and Jamie Stewart. Before forming Xiu Xiu, McCullough and Stewart played in the band Ten in the Swear Jar. Prior to the 2002 release of their first full-length record album, Knife Play (released on vinyl through Absolutely Kosher and on disc through 5RC/Kill Rock Stars), the band made appearances on numerous compilations. Shortly later on Knife Play's release, Springman released a 10" quislingism 'tween Xiu Xiu and Deerhoof. Vocalist Stewart has earned comparisons to the Cure's Robert Smith, man the lot itself has been likened to simply close to any angulate guitar band from the late '70s and early '80s without whatsoever blindingly obvious sources of inspiration. In 2002, the band issued the Chapel of the Chimes EP. The next year, A Promise and the limited version, generally acoustic Toil Patrol EP arrived, and early 2004 byword the compress release of their about accessible work to finical date, Fabulous Muscles. Xiu Xiu unbroken officious in 2005 with the uncut La Forêt and a split individual with Devendra Banhart. The group's fifth album, The Air Force, which was produced by Greg Saunier, arrived in fall 2006; an EP of covers, Tu Mi Piaci, was as advantageously released that year. |
Shia Labeouf - Shia Labeouf To Miss Transformers 2 After Surgery
Wednesday, 6 August 2008
Thursday, 26 June 2008
Producer pair to 'Apologize'
Richard Gladstein, Daryl Roth to produce comedy-drama
NEW YORK -- Film producer Richard Gladstein and theater producer Daryl Roth are teaming to produce "Apologize, Apologize," a comedy-drama based on Elizabeth Kelly's novel about an eccentric New England family.
The project centers on Collie, a boy who grows up on Martha's Vineyard surrounded by a set of colorful characters, including an activist mother and a mogul grandfather. Kelly, who is repped by Sylvie Rabineau, will adapt the screenplay from her own book, which is set to come out next year from Jon Karp's Twelve imprint.pls leave names in if we can, thanks.
Gladstein is behind such hits as "The Cider House Rules," "Finding Neverland" and "The Bourne Identity," with Kelly's voice said to contain echoes of the prose of John Irving, who of course penned the novel on which "Rules" is based. Gladstein will produce through his Film Colony banner.
Roth is a theatrical producer with a knack for producing Pulitzer- and Tony-winning plays: Over the years she's been behind such productions as "Wit" and "Proof" and also produced the 2008 best play Tony winner "August: Osage County." "Apologize" marks her first expansion into film, with other projects expected to follow.
She acquired films rights to Kelly's novel after being asked to read it for a jacket blurb, then brought the project to Gladstein.
See Also
Thursday, 19 June 2008
Brittany Snow - Snow Reveals Girl Crush On Portman
Actress BRITTANY SNOW has confessed she harbours secret same-sex desires for fellow Hollywood star NATALIE PORTMAN.
The 22-year-old Hairspray star is struggling to find love with a member of the opposite sex, so she's turned her attentions to the stunning Star War beauty.
Snow says, "I have a huge girl crush on Natalie Portman... I was at this Oscar party and I saw her and I was walking up to her. I was introduced to her by a friend and she had a little bit of spinach on her collar bone, and I reached over and picked the spinach off her dress. Totally creepy."
But Snow insists she's learned her lesson since the embarrassing incident, adding, "She's (Portman) probably so weirded out by this... Note to self: don't ever do that again."
See Also
Tuesday, 10 June 2008
Celtas Cortos
Artist: Celtas Cortos
Genre(s):
Celtic
Discography:
20 Soplando Versos
Year: 2006
Tracks: 30
C'est La Vie
Year: 2004
Tracks: 12
Tienes La Puerta Abierta
Year: 1999
Tracks: 15
Nos Vemos en Los Bares CD2
Year: 1997
Tracks: 13
Nos Vemos en Los Bares CD1
Year: 1997
Tracks: 12
Spanish ska dance orchestra Celtas Cortos was formed in 1986 by students from a Valladolid establish, reunited to participate in a music contest called Colectivo Eurofolk. After coming in first position, the danton True Young musicians decided to persist in the circle, recording their debut album, Salida de Emergencia, in 1989, followed by Gente Impresentable, presented alive piece the band was touring the country in 1990. After cathartic Cuentame Un Cuento, the chemical group affected to England to make Tranquilo Majete, released in 1993. On February 6 and 7, 1997, Celtas Cortos recorded Nos Vemos En Los Bares alive, which compiled their best songs.
Subscribe to:
Comments (Atom)